960298-98-0 Usage
Uses
Used in Pharmaceutical Research:
BCPM is used as a synthetic intermediate for the development of new drugs in the pharmaceutical industry. Its unique structure and reactivity allow for the creation of a wide range of biologically active compounds, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, BCPM is employed as a crucial component in the synthesis of various complex molecules. Its versatility and compatibility with different reaction conditions make it an indispensable tool for chemists working on novel molecular structures.
Used in Material Science:
BCPM also holds potential in material science, where it can be used to develop novel materials with specific properties. Its unique chemical structure allows for the creation of materials with tailored characteristics, such as improved stability or enhanced reactivity, depending on the desired application.
Check Digit Verification of cas no
The CAS Registry Mumber 960298-98-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,6,0,2,9 and 8 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 960298-98:
(8*9)+(7*6)+(6*0)+(5*2)+(4*9)+(3*8)+(2*9)+(1*8)=210
210 % 10 = 0
So 960298-98-0 is a valid CAS Registry Number.
960298-98-0Relevant academic research and scientific papers
QUINOLINE COMPOUNDS AND METHODS OF USE
-
, (2008/06/13)
Compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [ Formula I]
